An Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, 3-Sequence, Crossover Design, Relative Bioavailability Study Comparing the Pharmacokinetics of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations (ATV and COBI Oral Mini-tablets; 300 mg and 150 mg, Respectively) and the Coadministration of the Individual Reference Products (REYATAZ [Atazanavir Oral Powder] and TYBOST [Cobicistat Oral Tablet]; 300 mg and 150 mg, Respectively) in Healthy Adults Under Fed Conditions

简要总结

主要结局

次要结局

• Apparent terminal plasma half-life (T-HALF)(Up to 17 days)
• Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-T])(Up to 17 days)
• Observed plasma concentration at 24 hours (C24)(Up to 17 days)
• Time of maximum observed plasma concentration (Tmax)(Up to 17 days)
• Number of participants with Adverse Events (AEs)(Up to 75 days)
• Number of participants with vital sign abnormalities(Up to 17 days)
• Changes in Taste Evaluation Questionnaire(Up to 17 days)
• Number of participants with clinical laboratory abnormalities(Up to 17 days)
• Number of participants with electrocardiogram (ECG) abnormalities(Up to 17 days)
• Number of participants with Serious Adverse Events (SAEs)(Up to 75 days)
• Number of participants with AEs leading to discontinuation(Up to 75 days)
• Number of participants with AEs leading to death(Up to 75 days)